Site Management Organization (Panthera Biopartners) launched its first clinical trials site in the UK. Based in Preston, in northern England, the new clinical investigational site is open for studies—independent Panthera Biopartners (Panthera) has three clinical trials already in the pipeline.
Panthera Biopartners Background
Founded by Dr. Ian Smith, founder of Synexus (the world’s largest SMO) in December 2018, he is one of the co-founders of the independently controlled SMO Panthera. The other co-founder is Professor John Lyon, who was previously a global executive at CRO Covance. The company is presently working on raising an “A” round of financing which they report in a press release will be concluded shortly. The SMO is presently recruiting a CEO.
The First Site
The first Panthera clinical investigational site is based in Preston, Lancashire, UK in October, 2019. More sites are planned in Glasgow and Rochdale in early 2020 with further sites under negotiation.
SMO Focus Area
SMO will expand its network of clinical investigational sites with the aim of recruiting patients and running clinical trials in therapy areas which are traditionally managed in primary care including cardiac disease, allergies, migraine, osteoarthritis, osteoporosis and diabetes. Additionally the company will expand into NASH, Neurology and Oncology into the new year.
Study Start up Expertise
The SMO brings considerable expertise in important areas such as study start up and site activation cycle times. For example, founding team members (and management) has extensive experience in patient recruitment and the conduct of clinical trials.
Call to Action: Interested in clinical investigational sites in the UK—connect with Panthera Biopartners.